Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

602 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL, Januszewski AS, O'Connell R, Buizen L, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Rye KA, Keech AC; FIELD study investigators. Ong KL, et al. Among authors: taskinen mr. Diabetologia. 2015 Sep;58(9):2035-44. doi: 10.1007/s00125-015-3652-2. Epub 2015 Jun 9. Diabetologia. 2015. PMID: 26055067 Clinical Trial.
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL, Januszewski AS, O'Connell R, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Hung WT, Scott RS, Taskinen MR, Keech AC, Rye KA. Ong KL, et al. Among authors: taskinen mr. Diabetologia. 2015 Mar;58(3):464-73. doi: 10.1007/s00125-014-3458-7. Epub 2014 Nov 26. Diabetologia. 2015. PMID: 25425220 Clinical Trial.
Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study.
Ong KL, O'Connell R, Januszewski AS, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Waldman B, Colman PG, Best JD, Simes JR, Rye KA, Keech AC; FIELD study investigators. Ong KL, et al. Among authors: taskinen mr. Clin Chem. 2017 Jul;63(7):1261-1270. doi: 10.1373/clinchem.2016.270876. Epub 2017 Jun 12. Clin Chem. 2017. PMID: 28606915
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study.
Cao JY, Waldman B, O'Connell R, Sullivan DR, Scott RS, Aryal N, Gebski V, Marschner I, Taskinen MR, Simes JR, McGill N, Jenkins AJ, Keech AC; FIELD investigators. Cao JY, et al. Among authors: taskinen mr. Diabetes Obes Metab. 2020 Aug;22(8):1388-1396. doi: 10.1111/dom.14046. Epub 2020 Apr 22. Diabetes Obes Metab. 2020. PMID: 32243036 Clinical Trial.
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Scott R, et al. Among authors: taskinen mr. Diabetes Care. 2009 Mar;32(3):493-8. doi: 10.2337/dc08-1543. Epub 2008 Nov 4. Diabetes Care. 2009. PMID: 18984774 Free PMC article. Clinical Trial.
602 results